PL3458067T3 - Leczenie chorób neurologicznych - Google Patents
Leczenie chorób neurologicznychInfo
- Publication number
- PL3458067T3 PL3458067T3 PL17725862T PL17725862T PL3458067T3 PL 3458067 T3 PL3458067 T3 PL 3458067T3 PL 17725862 T PL17725862 T PL 17725862T PL 17725862 T PL17725862 T PL 17725862T PL 3458067 T3 PL3458067 T3 PL 3458067T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- neurological diseases
- neurological
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16170107 | 2016-05-18 | ||
| EP17725862.1A EP3458067B1 (en) | 2016-05-18 | 2017-05-17 | Treatment of neurological disorders |
| PCT/EP2017/025136 WO2017198346A1 (en) | 2016-05-18 | 2017-05-17 | Treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3458067T3 true PL3458067T3 (pl) | 2021-12-13 |
Family
ID=56024138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17725862T PL3458067T3 (pl) | 2016-05-18 | 2017-05-17 | Leczenie chorób neurologicznych |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20190284178A1 (pl) |
| EP (1) | EP3458067B1 (pl) |
| JP (1) | JP6991158B2 (pl) |
| KR (1) | KR102472461B1 (pl) |
| CN (1) | CN109475560B (pl) |
| AU (1) | AU2017265383B2 (pl) |
| CA (1) | CA3022753C (pl) |
| CY (1) | CY1124051T1 (pl) |
| DK (1) | DK3458067T3 (pl) |
| ES (1) | ES2863250T3 (pl) |
| HR (1) | HRP20210477T1 (pl) |
| HU (1) | HUE053494T2 (pl) |
| IL (1) | IL263080B (pl) |
| LT (1) | LT3458067T (pl) |
| MX (1) | MX2018014168A (pl) |
| PL (1) | PL3458067T3 (pl) |
| PT (1) | PT3458067T (pl) |
| RS (1) | RS61655B1 (pl) |
| RU (1) | RU2765868C2 (pl) |
| SG (1) | SG11201809792TA (pl) |
| SI (1) | SI3458067T1 (pl) |
| SM (1) | SMT202100177T1 (pl) |
| TW (1) | TWI753912B (pl) |
| WO (1) | WO2017198346A1 (pl) |
| ZA (1) | ZA201807393B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018140001A (ru) | 2016-05-18 | 2020-06-18 | Пикур Терапьютикс Аг | Лечение повреждений кожи |
| DK3458067T3 (da) * | 2016-05-18 | 2021-04-06 | Univ Basel | Behandling af neurologiske lidelser |
| MX2020005024A (es) | 2017-11-23 | 2020-08-13 | Piqur Therapeutics Ag | Tratamiento de trastornos de la piel. |
| CN117396470A (zh) * | 2021-04-09 | 2024-01-12 | 巴塞尔大学 | 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物 |
| KR20240008312A (ko) * | 2021-04-09 | 2024-01-18 | 유니버시타트 바셀 | Pi3k의 가역적 및 비가역적 공유 억제제로서의 트리아진 유도체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| ZA200807111B (en) * | 2006-02-09 | 2009-11-25 | Alba Therapeutics Corp | Formulations for a tight junction effector |
| CL2007001167A1 (es) | 2006-04-26 | 2008-01-25 | Genentech Inc | Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica. |
| JP4450857B2 (ja) * | 2006-08-08 | 2010-04-14 | 中外製薬株式会社 | Pi3k阻害剤としてのピリミジン誘導体およびその用途 |
| ATE551334T1 (de) | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
| TR201906123T4 (tr) | 2008-05-23 | 2019-05-21 | Wyeth Llc | P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri. |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US9556203B2 (en) | 2013-10-04 | 2017-01-31 | Piqur Therapeutics Ag | Conformationally restricted P13K and mTOR inhibitors |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| AU2017265384B2 (en) | 2016-05-18 | 2023-02-23 | The Trustees Of The University Of Pennsylvania | Treatment of skin lesions |
| RU2018140001A (ru) * | 2016-05-18 | 2020-06-18 | Пикур Терапьютикс Аг | Лечение повреждений кожи |
| DK3458067T3 (da) * | 2016-05-18 | 2021-04-06 | Univ Basel | Behandling af neurologiske lidelser |
-
2017
- 2017-05-17 DK DK17725862.1T patent/DK3458067T3/da active
- 2017-05-17 PT PT177258621T patent/PT3458067T/pt unknown
- 2017-05-17 HR HRP20210477TT patent/HRP20210477T1/hr unknown
- 2017-05-17 SI SI201730696T patent/SI3458067T1/sl unknown
- 2017-05-17 RS RS20210393A patent/RS61655B1/sr unknown
- 2017-05-17 WO PCT/EP2017/025136 patent/WO2017198346A1/en not_active Ceased
- 2017-05-17 LT LTEP17725862.1T patent/LT3458067T/lt unknown
- 2017-05-17 CN CN201780029954.7A patent/CN109475560B/zh active Active
- 2017-05-17 EP EP17725862.1A patent/EP3458067B1/en active Active
- 2017-05-17 JP JP2018560457A patent/JP6991158B2/ja active Active
- 2017-05-17 RU RU2018140013A patent/RU2765868C2/ru not_active Application Discontinuation
- 2017-05-17 SM SM20210177T patent/SMT202100177T1/it unknown
- 2017-05-17 KR KR1020187035896A patent/KR102472461B1/ko active Active
- 2017-05-17 US US16/301,729 patent/US20190284178A1/en not_active Abandoned
- 2017-05-17 PL PL17725862T patent/PL3458067T3/pl unknown
- 2017-05-17 SG SG11201809792TA patent/SG11201809792TA/en unknown
- 2017-05-17 MX MX2018014168A patent/MX2018014168A/es unknown
- 2017-05-17 ES ES17725862T patent/ES2863250T3/es active Active
- 2017-05-17 CA CA3022753A patent/CA3022753C/en active Active
- 2017-05-17 AU AU2017265383A patent/AU2017265383B2/en active Active
- 2017-05-17 HU HUE17725862A patent/HUE053494T2/hu unknown
- 2017-05-18 TW TW106116465A patent/TWI753912B/zh active
-
2018
- 2018-11-05 ZA ZA2018/07393A patent/ZA201807393B/en unknown
- 2018-11-18 IL IL263080A patent/IL263080B/en unknown
-
2020
- 2020-12-17 US US17/125,012 patent/US11878972B2/en active Active
-
2021
- 2021-03-26 CY CY20211100267T patent/CY1124051T1/el unknown
-
2023
- 2023-12-01 US US18/526,732 patent/US20240343718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE060711T2 (hu) | Makrociklusos vegyületek betegségek kezelésére | |
| PL3416631T3 (pl) | Środki terapeutyczne do leczenia chorób neurodegeneracyjnych | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| PL3169328T3 (pl) | Pochodne chinoliny do leczenia chorób zapalnych | |
| EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| IL257764B (en) | Methods for treatment of diseases | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| IL263080B (en) | Treatment of neurological disorders | |
| IL264603A (en) | Reelin compositions for treatment of neurological disorders | |
| IL262801A (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| DK3182980T3 (da) | Behandling af glykosyleringsmangelsygdomme | |
| PL3302499T3 (pl) | Leczenie chorób mitochondrialnych | |
| IL263837A (en) | Treatment of ocular disease | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201706662D0 (en) | Treatment of neurological diseases |